RecruitingNCT05919511
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)
Sponsor
Incyte Corporation
Enrollment
1,500 participants
Start Date
Aug 1, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Age ≥ 18 years inclusive at the time of signing the ICF
- Allogeneic SCT 90 to 180 days prior to enrollment
- Able to comprehend and willing to provide informed consent
- Willing and able to complete participant-assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERNon-Interventional
This is an observational study
Locations(32)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05919511
Related Trials
A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD)
NCT072532591 location
Treatment of Refractory cGVHD by Donor-derived Treg Cell Injection Combined With Recombinant Human Interleukin-2
NCT069201991 location
Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease
NCT066637221 location